MicroPort Scientific (HK:0853) has released an update.
MicroPort Scientific anticipates a significant profit rise for its subsidiary, Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd., for the first half of 2024, with expected revenue and net profit increases of 25-30% and 40-50%, respectively. This financial boost is credited to the robust sales performance of innovative products in the vascular intervention markets. Investors are advised to consider that these preliminary, unaudited figures are specific to EV MedTech and do not reflect the entire Group’s financials.
For further insights into HK:0853 stock, check out TipRanks’ Stock Analysis page.
